Aa
Aa
A
A
A
Close
382218 tn?1341181487

Neuromyelitis optica: not a multiple sclerosis variant

Interesting paper I stumbled across tonight, clarifying the current thinking about NMO as opposed to the traditional belief that it was simply a more rare, debilitating form of MS.  Because it is not, correct diagnosis is so important, as targeted treatments for each respective disease are so different.

Neuromyelitis optica: not a multiple sclerosis variant.
Barnett MH, Sutton I.
Source
Department of Neurology, Royal Prince Alfred Hospital, Missenden Road, Camperdown, New South Wales, Australia. michael.***@****

Abstract
PURPOSE OF REVIEW:
The discovery of neuromyelitis optica (NMO)-immunoglobulin (Ig)G and its target antigen aquaporin 4 (AQP4) redefined NMO, historically considered a multiple sclerosis (MS) variant, as a specific disease entity. NMO and MS have divergent responses to immunotherapy and it is important to distinguish the conditions at disease onset. In this article, we review new pathological, imaging and clinical trial data pertaining to NMO, and discuss emerging concepts of molecular immunopathogenesis in NMO that can inform the development of targeted therapies.

RECENT FINDINGS:
Recent studies illustrate the range of brain lesions associated with NMO, and the importance of diagnostic biomarkers in patients with atypical or limited presentations. Neuropathological studies showing perivascular astrocyte destruction and preserved myelin in early NMO lesions indicate a pathogenesis distinct from MS. Characterisation of NMO-IgG binding to AQP4 isoforms and the development of novel disease models have elucidated complement-mediated and cell-mediated mechanisms of astrocyte injury.

SUMMARY:
NMO-IgG positive NMO is not an MS variant. Further work is required to delineate the pathogenesis of NMO syndromes without antibodies to AQP4. Methodological flaws inherent to small, open label trials of current NMO therapies limit extrapolation to clinical practice. In the coming years, NMO will be treated with targeted therapies that are emerging from an enhanced understanding of the molecular immunopathogenesis of the disease.

http://www.ncbi.nlm.nih.gov/pubmed/22487568?dopt=Abstract

3 Responses
Sort by: Helpful Oldest Newest
198419 tn?1360242356
Excellent DB! Thank you!
Helpful - 0
Avatar universal
interesting, I attended an MS support group meeting tonight and the person who runs the group, was diagnosed with MS back in 1970 and has just been told she has NMO and not MS due to her lesions being "atypical" in shape, and the first med they put her on, has damaged her liver, so they are going to put her on something else, nice lady, so sad.

I had never heard of it before tonight
Helpful - 0
739070 tn?1338603402
Excellent article (abstract)!  What  great breakthrough in research for those with NMO so they receive the correct treatment. I found the pathogensis of the disease very interesting since the mylein IS preserved.

Thanks for sharing!!!!!!!!!

Ren
Helpful - 0
Have an Answer?

You are reading content posted in the Multiple Sclerosis Community

Top Neurology Answerers
987762 tn?1671273328
Australia
5265383 tn?1669040108
ON
1756321 tn?1547095325
Queensland, Australia
1780921 tn?1499301793
Queen Creek, AZ
Learn About Top Answerers
Didn't find the answer you were looking for?
Ask a question
Popular Resources
Find out how beta-blocker eye drops show promising results for acute migraine relief.
In this special Missouri Medicine report, doctors examine advances in diagnosis and treatment of this devastating and costly neurodegenerative disease.
Here are 12 simple – and fun! – ways to boost your brainpower.
Discover some of the causes of dizziness and how to treat it.
Discover the common causes of headaches and how to treat headache pain.
Two of the largest studies on Alzheimer’s have yielded new clues about the disease